<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00540085</url>
  </required_header>
  <id_info>
    <org_study_id>2007-003005-27</org_study_id>
    <secondary_id>H-B-2007-038</secondary_id>
    <nct_id>NCT00540085</nct_id>
  </id_info>
  <brief_title>Pharmacodynamic Trial on Rocuronium in Obese Patients</brief_title>
  <official_title>Pharmacodynamic Trial on Rocuronium in Obese Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim: To optimize the use of rocuronium (a neuromuscular blocking agent) in obese patients
      undergoing gastric bypass or gastric banding.

      Background: During general anaesthesia, a neuromuscular blocking agent is needed to allow
      surgery and airway management. Optimal dosing is important in order to avoid inadequately
      muscle relaxation, but also to avoid overdosage, which can result in prolonged anaesthesia
      and respiratory complications.

      Main hypothesis: Rocuronium dosed according to ideal body weight results in shorter duration
      of action compared to rocuronium dosed according to corrected body weight without prolonged
      onset time or compromised airway management or surgical demands for muscle relaxation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of action, defined as: Time to reappearance of T4.</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete duration of action, defined as: Time to TOF-ratio = 0.9</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Onset time</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Bariatric Surgery</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rocuronium dosed after ideal body weight</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rocuronium dosed after corrected body weight 20%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rocuronium dosed after corrected body weight 40%</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rocuronium</intervention_name>
    <description>0.6 mg/kg given intravenously before intubation</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
    <other_name>Esmeron (R)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-65 years.

          -  Elective laparoscopic gastric banding or gastric bypass.

        Exclusion Criteria:

          -  Expected difficult endotracheal intubation based on anatomic or pathologic findings or
             history.

          -  Known or suspected neuromuscular disease, known to affect the neuromuscular blockade.

          -  Severely impaired renal or hepatic function, as evaluated by the investigator.

          -  Known or suspected allergy to drugs used in the trial.

          -  Daily or expected use during the trial of the following drugs, known to affect
             neuromuscular transmission: Inhalational anaesthetics, magnesiumsalts, clindamycin,
             polymyxins and aminoglycosides (gentamicin, neomycin, netilmicin, streptomycin og
             tobramycin).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lars S Rasmussen, MD, DMSc</last_name>
    <role>Study Chair</role>
    <affiliation>Department of anaesthesia, Centre of Head and Orthopaedics, Copenhagen University Hospital, Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christian S Meyhoff, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of anaesthesia, Centre of Head and Orthopaedics, Copenhagen University Hospital, Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Casper Claudius, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Department of anaesthesia, Centre of Head and Orthopaedics, Copenhagen University Hospital, Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jørgen Viby-Mogensen, Prof., DMSc</last_name>
    <role>Study Director</role>
    <affiliation>Department of anaesthesia, Centre of Head and Orthopaedics, Copenhagen University Hospital, Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jørgen Lund, MD</last_name>
    <role>Study Director</role>
    <affiliation>Department of anaesthesia, Privathospitalet Hamlet A/S, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Morten Jenstrup, MD</last_name>
    <role>Study Director</role>
    <affiliation>Department of anaesthesia, Privathospitalet Hamlet A/S, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anne Marie Sørensen, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Department of anaesthesia, Centre of Head and Orthopaedics, Copenhagen University Hospital, Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of anaesthesia, Privathospitalet Hamlet A/S</name>
      <address>
        <city>Copenhagen</city>
        <zip>DK-2000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <results_reference>
    <citation>Meyhoff CS, Lund J, Jenstrup MT, Claudius C, Sørensen AM, Viby-Mogensen J, Rasmussen LS. Should dosing of rocuronium in obese patients be based on ideal or corrected body weight? Anesth Analg. 2009 Sep;109(3):787-92. doi: 10.1213/ane.0b013e3181b0826a.</citation>
    <PMID>19690247</PMID>
  </results_reference>
  <verification_date>October 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 4, 2007</study_first_submitted>
  <study_first_submitted_qc>October 4, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2007</study_first_posted>
  <last_update_submitted>October 15, 2009</last_update_submitted>
  <last_update_submitted_qc>October 15, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 16, 2009</last_update_posted>
  <responsible_party>
    <name_title>Lars S. Rasmussen</name_title>
    <organization>Department of Anaesthesia, HOC, Copenhagen University Hospital, Rigshospitalet</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rocuronium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

